A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis

Genzyme Europe BV0 个研究点目标入组 400 人开始时间: 2008年7月16日最近更新: 2012年8月14日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Genzyme Europe BV
入组人数: 400

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Patients must meet the following criteria to be enrolled in the study:
•1. Willing and able to provide written informed consent.
•2. Men or women 18 years of age or older.
•3. If currently on phosphate binder(s), willing to stop the phosphate binder and enter a 14-21 day Washout Period.
•4. Have been, in the opinion of the Investigator, stable on a phosphate-controlled diet at Screening and be willing to avoid any intentional changes, such as fasting or dieting for the duration of the study.
•5. Have the following central laboratory measurements:
•If not taking a phosphate binder at Screening, a serum phosphorous measurement =4.6 mg/dL (=1.49 mmol/L) and =5.5 mg/dL (=1.76 mmol/L) at Screening.
•If taking a phosphate binder at Screening, a serum phosphorous measurement =4.6 mg/dL (=1.49mmol/L) and =5.5 mg/dL (=1.76 mmol/L) after the 14-21 day Washout Period; at the Post-Washout Visit.
•6. Willing and able to take the Investigational Product as a phosphate binder for the duration of the study.
•7. Willing and able to maintain screening doses of lipid-lowering medication for the duration of the study, except for safety reasons.
•8. Willing and able to maintain doses of medication for control of hyperparathyroidism from Screening through Week 12, except for safety reasons.
•9. Willing and able to avoid antacids and phosphate binders containing aluminium, magnesium, calcium or lanthanum for the duration of the study unless prescribed as an evening calcium supplement.
•10. Willing, if female and of childbearing potential (pre-menopausal and not surgically sterile), to use an effective contraceptive method throughout study, which includes barrier methods, hormones, or intrauterine device(s).
•11. Expecting not to initiate dialysis or have a kidney transplant for the duration of this study.
•12. Be considered compliant with phosphate binders (if applicable).
•13. Has not participated in any other investigational drug studies within 30 days prior to enrolment.
•14. Have a level of understanding and willingness to cooperate with all visits and procedures as described by the study personnel.
•15. Able to be contacted by phone or other remote means in order to be informed of Investigational Product dose changes.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Patients will be excluded from this study if they do not meet the specific inclusion criteria, or if they are/have:
•1. Active dysphagia or swallowing disorder or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation.
•2. Previous major gastrointestinal tract surgery.
•3. In the opinion of the Investigator, active ethanol or drug abuser, excluding tobacco use.
•4. Use of anti-arrhythmics for arrhythmias or anti-seizure medications for seizures.
•5. At Screening, the following central laboratory measurements:
•Serum 25-hydroxyvitamin D <10 ng/mL (<25 nmol/L),
•Serum intact parathyroid hormone (iPTH) =600 pg/mL (=66 pmol/L), and
•Serum LDL >140 mg/dL (>3.59 mmol/L).
•6. In the opinion of the Investigator, any clinically significant unstable medical condition, for example:
•poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, HIV infection.
•7. Pregnant or breast-feeding.
•8. Evidence of active malignancy except for basal cell carcinoma of the skin.
•9. Unable to comply with the requirements of the study.
•10. A known hypersensitivity to the Investigational Product or any of its constituents.
•11. Any other condition, which in the opinion of the Investigator, would mean participation in the study would not be in the patient’s best interest.

研究者

发起方

Genzyme Europe BV

相似试验

进行中（未招募）

1 期

A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on DialysisTreatment of hyperphosphataemiaMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney disease

EUCTR2007-003885-16-FRGenzyme Europe BV400

进行中（未招募）

不适用

A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coronary SyndromeCoronary Artery DiseaseMedDRA version: 9.1Level: PTClassification code 10011078Term: Coronary artery disease

EUCTR2006-000296-15-BEEisai Limited600

进行中（未招募）

不适用

EUCTR2007-003885-16-GRGenzyme Europe BV400

已完成

2 期

NL-OMON34002PRA Belgium BVBA16

进行中（未招募）

1 期

A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for 9 Months in Subjects Undergoing Bilateral Nerve-Sparing Radical Prostatectomy - LVIKErectile dysfunction following Bilateral Nerve-Sparing Radical ProstatectomyMedDRA version: 12.0 Level: LLT Classification code 10050756 Term: Radical prostatectomyMedDRA version: 12.0 Level: LLT Classification code 10061461 Term: Erectile dysfunction

EUCTR2009-011850-17-GBEli Lilly and Company Limited